Phase 1 Study of CH505 HIV Vaccine Nanoparticles and mRNA Boosters in Healthy Adults
Public ClinicalTrials.gov record NCT07757802. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Clinical Trial to Evaluate the Safety and Immunogenicity of ACU-026-001-1-Adjuvanted CH505 Protein Nanoparticles (DV901-NP) Alone or Boosted With CH505 NP (DV902-NP) or CH505 mRNAs in Adults in Overall Good Health Without HIV
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This Phase 1 study will evaluate the safety, tolerability, and immune responses of investigational CH505 HIV vaccine regimens in adults in overall good health without HIV. Participants will receive CH505 protein nanoparticle vaccines (DV901-NP) formulated with the investigational adjuvant ACU-026-001-1, followed by either CH505 protein nanoparticle (DV902-NP) or CH505 mRNA vaccine boosters. The study will assess the ability of these regimens to induce HIV-specific immune responses, including B-cell responses associated with the development of broadly neutralizing antibodies. An immunology cohort will also evaluate how the location of booster vaccination affects immune responses.
Study identification
- NCT ID
- NCT07757802
- Recruitment status
- Not yet recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 54 participants
Conditions and interventions
Conditions
Interventions
- ACU-026-001-1 Biological
- CH505 TF mRNA-gp160 Biological
- CH505 w24 mRNA-gp160 Biological
- DV901-NP Biological
- DV902-NP Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years to 55 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 9, 2026
- Primary completion
- Jun 6, 2028
- Completion
- Oct 6, 2028
- Last update posted
- Aug 10, 2026
2026 – 2028
United States locations
- U.S. sites
- 8
- U.S. states
- 6
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Bridge HIV CRS Site# 30305 | San Francisco | California | 94102 | — |
| The Ponce de Leon Center CRS Site# 5802 | Atlanta | Georgia | 30308 | — |
| Brigham and Women's Hospital Vaccine CRS (BWH VCRS) Site# 30007 | Boston | Massachusetts | 02115 | — |
| BIDMC VCRS Site# 32077 | Boston | Massachusetts | 02215 | — |
| University of Rochester Vaccines to Prevent HIV Infection CRS Site# 31467 | Rochester | New York | 14642 | — |
| Penn Prevention CRS Site# 30310 | Philadelphia | Pennsylvania | 19104 | — |
| University of Pittsburgh CRS Site# 1001 | Pittsburgh | Pennsylvania | 15213 | — |
| Vanderbilt Vaccine (VV) CRS Site# 30352 | Nashville | Tennessee | 37232 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated HIV trials
Other public records listing HIV. Sorted by last update posted; newest first. Not a recommendation.
- NCT07769580: Project SPACE: Testing Daily Text Messages to Reduce Alcohol Use and HIV Risk Behavior Not yet recruiting
- NCT07762066: Bridge to Belonging: Peer Led Intervention to Reduce Loneliness and Depression Among Older Gay and Bisexual Men Recruiting
- NCT07502365: BIG Chicago: A Trial of Basic Income Guarantee for Young People Living With HIV Recruiting
- NCT06930508: Bringing Medicines for HIV Prevention to a Family Planning Clinic Recruiting
- NCT07728370: RISE: Reducing Cancer and HIV Stigma Through Empowerment Not yet recruiting
- NCT07637669: Olfactory Function and Model-Based Behavior in People Living With HIV and SUD Not yet recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07757802, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 10, 2026 · Synced Aug 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07757802 live on ClinicalTrials.gov.